Kevin Forrest, Chief Scientific Officer at Cidara Therapeutics, Inc. (CDTX), bought 12,500 shares at $7.75 ($97K) on 2017-03-31, disclosed to the SEC on 2017-04-04.
Open-market purchase of $97k CDTX by Chief Scientific Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |